REATA PHARMACEUTICALS INC: debt financing — Reata Pharmaceuticals closes $50M Tranche B loan under $275M facility

REATA PHARMACEUTICALS INC

Closed $50 million Tranche B loan on July 10, 2023, under $275 million loan agreement.
Funding triggered by FDA approval of the company's prior approval submission.
Loan agreement initially entered on May 5, 2023, with BPCR Limited Partnership and BioPharma Credit.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

REATA PHARMACEUTICALS INC incurred term loan of $50 million with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC.

Instrument: term loan
Principal: $50 million
Counterparty: BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC
Event: incurrence

Exact text from the filing

On July 10, 2023, the Borrower closed the second Tranche (the Tranche B Loan) of $50 million under the Loan Agreement.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

REATA PHARMACEUTICALS INC entered into Loan Agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC valued at up to $275 million (effective 2023-05-05).

Action: entry
Agreement: credit facility
Counterparty: BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC
Value: up to $275 million
Effective: 2023-05-05

Exact text from the filing

On May 5, 2023, we, as the Borrower, and certain of our direct and indirect subsidiaries party thereto from time to time, as the guarantors, entered into a loan agreement (the Loan Agreement) with BPCR Limited Partnership (as a Lender), BioPharma Credit Investments V (Master) LP (as a Lender), and BioPharma Credit PLC, as collateral agent for the Lenders, pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate amount of up to $275 million.

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0000950170-23-032425

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.